• Ilke Erbay, Naile Eris Gudul, Ugur Kokturk, Pelin Aladag, Meltem Kandazoglu, and Ahmet Avci.
• Med Princ Pract. 2024 Oct 22: 1251-25.

ObjectiveImplantable cardioverter defibrillators (ICDs) are the standard treatment for patients with reduced left ventricular ejection fraction (LVEF≤35%) to reduce the risk of sudden cardiac death. Loop diuretics can cause electrolyte imbalances leading to an increased incidence of ICD shocks. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown cardiovascular benefits in patients with heart failure (HF), but their effects on ventricular arrhythmias and ICD shocks, particularly in patients receiving different doses of loop diuretics, are not fully understood. This study evaluated the effects of furosemide dose and SGLT2i use on ICD shocks in HF patients with reduced left ventricular ejection fraction (HFrEF).Materials And MethodsHFrEF patients using oral furosemide and undergoing ICD implantation in our clinic were followed for 12 months to monitor ICD shocks for ventricular arrhythmias. They were grouped according to daily oral furosemide dose and SGLT2i use.ResultsOut of 175 patients, the use of high-dose furosemide (>80 mg/day) was significantly higher in the ICD shock group compared to the non-shock group (38.8% vs. 16.7%, p = 0.001), while the use of SGLT2i was lower (19.4% vs. 45.4%, p < 0.001). ICD shocks occurred in 67.6% of patients on high-dose furosemide without SGLT2i and 30.0% with SGLT2i (p < 0.001). Multivariate analysis identified the absence of SGLT2i as an independent predictor of ICD shocks.ConclusionsSGLT2i was associated with reduced ventricular arrhythmias and ICD shocks in HF patients, even when high doses of furosemide were used. The absence of SGLT2i in HF treatment was an independent predictor of ICD shocks.The Author(s). Published by S. Karger AG, Basel.

9 keywords...

hide…